BioInvent International
8.12.2021 08:21:38 CET | ACCESS Newswire | Press release
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)
- BioInvent's pipeline expanding to four drug candidates in five clinical trials
Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
BI-1607 targets FcyRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcyRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.
BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.
"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676499/BioInvent-has-Submitted-a-CTA-for-a-Phase-12a-trial-of-BI-1607-a-Novel-anti-FcyRIIB-Antibody-for-the-Treatment-of-Patients-with-Solid-Tumors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
IXOPAY Appoints Ajoy Krishnamoorthy as CEO to Accelerate Growth and Advance Payments for the Agentic Age25.8.2026 12:00:00 CEST | Press release
Enterprise Software and Commerce Leader Will Guide IXOPAY's Next Development Phase of Its Unified, AI-Native Payments Infrastructure Platform DALLAS, TX / ACCESS Newswire / August 25, 2026 / IXOPAY, the payment infrastructure solution that enables fluid commerce, today announced the appointment of Ajoy Krishnamoorthy as CEO. Krishnamoorthy brings more than two decades of enterprise software leadership and extensive product engineering experience turning complex technologies into platforms that businesses depend on to grow. Krishnamoorthy joins IXOPAY at a pivotal moment, as it helps unlock fluid commerce for enterprise merchants. Krishnamoorthy will focus on bringing IXOPAY's modular product suite into the agentic age, providing merchants with the freedom to buy what they need and build what they want in scaling their global payment operations. He comes with a customer-first mindset, ensuring momentum is maintained, and support is given to customers during this seismic shift in the lan
LiberNovo Support Week Goes Live: Up to 44% Off on Maxis, Omni SE and Omni Pro Ergonomic Chair Series25.8.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / August 25, 2026 / LiberNovo Support Week is now open across the European Union and the United Kingdom. Through September 8, the Maxis Series, Omni SE, and Omni Pro are up to 44% off in the EU and up to 39% off in the UK, with three gift tiers and triple points for members. The name works two ways. Support your body. LiberNovo chairs respond as you lean in, sit upright, and recline, instead of holding you to one fixed posture. Support your journey. Through Create for Creators, LiberNovo backs the developers, designers, streamers, and gamers who do their work seated. Maxis Series: Built for Bigger Builds The event leads with the Maxis Series, sized from the frame up for taller, broader, and heavier users. A 52 cm seat depth supports more of the thigh, the wider cushion leaves room to shift, and the reinforced structure is rated to 181 kg. Five-stage recline control runs from 105° to 160° on progressive springs, so support holds steady at every angle, inc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom